Based on the company's long-term price-to-sales (P/S) multiple of 15.2, Novo Nordisk would only need to increase revenue at an average rate of 10% per year through 2030 to reach a trillion-dollar ...

Novo Nordisk has an estimated 62% market share of the GLP-1 agonist market, with archrival Eli Lilly accounting for another 35%. Investors are looking ahead to next-generation drugs that could ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

The company's forward price-to-earnings multiple of 50.2 is more than double that of the S&P 500, and significantly higher than Novo Nordisk's forward P/E multiple of 32.7.

Novo Nordisk was the talk of the pharma and medical world this year — and also the world of People magazine and E! with stars from Amy Schumer to Elon Musk using the firm’s diabetes and weight ...

Novo Nordisk is a high-quality pharmaceutical company with a unique ownership structure, controlled by a charitable foundation. The company specializes in diabetes and obesity treatments, with a ...

Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing weight-loss drugs. The short-lived partnership, announced in April ...

Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G ...

Novo Nordisk's chair, Helge Lund, said that the company's strategy will remain unchanged and that the board is confident in the company's current business plans and its ability to execute.

Based on the company's long-term price-to-sales (P/S) multiple of 15.2, Novo Nordisk would only need to increase revenue at an average rate of 10% per year through 2030 to reach a trillion-dollar ...

The company's forward price-to-earnings multiple of 50.2 is more than double that of the S&P 500, and significantly higher than Novo Nordisk's forward P/E multiple of 32.7.